Cagrilintide: The Amylin Pathway in Weight Management Research

Cagrilintide (formerly NN9838) is a long-acting analog of amylin — a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. While GLP-1 receptor agonists like semaglutide have become the most recognized weight management peptides, cagrilintide represents a mechanistically distinct approach targeting the amylin receptor system (AMY1, AMY2, and AMY3 receptors) in the area postrema and nucleus tractus solitarius of the brainstem.

Native amylin (also called islet amyloid polypeptide or IAPP) has a half-life of only 13 minutes, limiting its therapeutic utility. Cagrilintide was engineered with strategic amino acid substitutions and a C18 fatty acid chain that enables albumin binding, extending its half-life to approximately 160 hours — allowing once-weekly subcutaneous injection. This pharmacokinetic profile makes it practical for sustained appetite regulation.

Cagrilintide activates amylin receptors in the hindbrain to reduce meal size, slow gastric emptying, and suppress post-meal glucagon secretion. Critically, the amylin pathway is neuroanatomically distinct from the GLP-1 pathway, though both converge on appetite-regulating circuits in the hypothalamus. This mechanistic independence is why combination therapy (cagrilintide + semaglutide, marketed as CagriSema) produces weight loss significantly greater than either agent alone. For a comprehensive overview of weight management peptides, see our peptide weight loss guide.

Understanding cagrilintide requires understanding the amylin system it targets — a hormone pathway that has been overshadowed by GLP-1 but plays an equally important role in metabolic regulation:

Amylin Secretion: Amylin is released from pancreatic beta cells in a 1:100 molar ratio with insulin. Every time food is consumed and insulin rises, amylin rises proportionally. In healthy individuals, amylin peaks approximately 15–30 minutes after a meal and returns to baseline within 2–3 hours. In type 2 diabetes and obesity, amylin secretion becomes dysregulated — initially excessive, then deficient as beta cell function deteriorates.

Central Nervous System Effects: Amylin crosses the blood-brain barrier and binds to receptors in the area postrema (AP) — a circumventricular organ with a permeable blood-brain barrier. Activation of AP amylin receptors triggers signals through the nucleus tractus solitarius (NTS) and lateral parabrachial nucleus, ultimately reaching the hypothalamic feeding centers. This pathway reduces meal size through satiation (within-meal fullness) rather than satiety (between-meal hunger), a distinction that differentiates it from GLP-1 signaling.

Gastric Motility: Amylin slows gastric emptying by 40–60% through vagal nerve signaling, extending the period over which nutrients are absorbed and maintaining postprandial satiation. This gastric slowing is additive with GLP-1-mediated gastric effects, contributing to the enhanced efficacy of combination approaches.

Glucagon Suppression: Amylin suppresses postprandial glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output. This effect complements insulin's glucose-lowering action and is particularly relevant in type 2 diabetes research, where glucagon dysregulation contributes significantly to hyperglycemia. Learn more about peptide mechanisms in our peptide science guide.

Cagrilintide has been evaluated in multiple clinical trials, with data supporting its efficacy both as monotherapy and in combination with GLP-1 agonists:

Phase 2 Monotherapy Trial (2021): A 26-week randomized, double-blind, placebo-controlled trial published in The Lancet enrolled 706 adults with overweight or obesity (BMI ≥30, or ≥27 with comorbidities) without diabetes. Participants received weekly subcutaneous cagrilintide at doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, or placebo. At the highest dose (4.5 mg), participants achieved a mean body weight reduction of 10.8% from baseline, compared to 3.0% with placebo. The dose-response relationship was clear and consistent.

CagriSema Phase 2 Trial (2023): The combination of cagrilintide 2.4 mg + semaglutide 2.4 mg weekly was evaluated in a 32-week trial of 92 adults with obesity. Mean body weight reduction reached 15.6% — significantly exceeding the 5.1% with cagrilintide alone and 8.2% with semaglutide alone in this study. This confirmed the hypothesis that amylin and GLP-1 pathway co-activation produces synergistic weight loss.

CagriSema Phase 3 (REDEFINE Program): The REDEFINE clinical trial program, comprising multiple phase 3 trials enrolling over 8,000 participants, is evaluating CagriSema for obesity and type 2 diabetes. Preliminary data from REDEFINE-1 reported at the American Diabetes Association Scientific Sessions showed mean weight reductions of approximately 22–25% at 68 weeks — approaching the efficacy of bariatric surgery without surgical intervention. Full results are expected to support regulatory submission in 2026.

Metabolic Benefits: Beyond weight loss, cagrilintide trials report improvements in waist circumference (mean reduction of 9.1 cm at 4.5 mg dose), HbA1c (0.3–0.4% reduction in non-diabetic subjects), triglycerides, and blood pressure. These cardiometabolic improvements suggest cagrilintide addresses the metabolic syndrome broadly, not just body weight.

Positioning cagrilintide within the broader landscape of weight management peptides clarifies its unique value and potential research applications:

Cagrilintide vs. Semaglutide: Semaglutide (a GLP-1 receptor agonist) targets the GLP-1R pathway, primarily reducing appetite through hypothalamic GLP-1 receptor activation. Cagrilintide targets the amylin receptor system, reducing meal size through hindbrain satiation circuits. As monotherapies, semaglutide 2.4 mg produces approximately 12–15% weight loss at 68 weeks (STEP 1 trial), while cagrilintide 4.5 mg produces approximately 10.8% at 26 weeks. The combination (CagriSema) produces 22–25%, confirming that these pathways are complementary rather than redundant.

Cagrilintide vs. Tirzepatide: Tirzepatide is a dual GIP/GLP-1 receptor agonist that achieved up to 22.5% weight loss in the SURMOUNT-1 trial. Cagrilintide targets an entirely different receptor system (amylin vs. incretin receptors). Theoretically, cagrilintide could be combined with tirzepatide for even greater efficacy — addressing three distinct appetite pathways — though this combination has not yet been studied clinically.

Cagrilintide vs. Pramlintide: Pramlintide (Symlin) is the only FDA-approved amylin analog, but it requires injection 2–3 times daily due to its short half-life. Cagrilintide's once-weekly dosing represents a significant improvement in convenience and compliance. Additionally, cagrilintide achieves higher and more sustained amylin receptor activation, producing greater weight loss than pramlintide (10.8% vs. approximately 3–4%). See our comprehensive weight loss peptide guide for comparisons across all categories.

Cagrilintide vs. AOD-9604: AOD-9604 is a fragment of human growth hormone that promotes lipolysis without GH-like effects on glucose or growth. It targets fat metabolism directly rather than appetite circuits. Cagrilintide works primarily through appetite reduction and gastric slowing. These distinct mechanisms suggest potential complementarity, though combination research has not been published.

Research protocols for cagrilintide follow the dose escalation schedules established in clinical trials — all for research reference only:

Standard Dose Escalation: Clinical trials use a gradual titration schedule to minimize gastrointestinal side effects: Week 1–4: 0.25 mg weekly. Week 5–8: 0.5 mg weekly. Week 9–12: 1.0 mg weekly. Week 13–16: 2.4 mg weekly. Week 17+: 4.5 mg weekly (maximum studied dose). Each dose level is maintained for 4 weeks before escalation, allowing receptor adaptation and minimizing nausea — the most common dose-limiting side effect.

Administration: Cagrilintide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection site should be rotated weekly. In clinical trials, injections were administered on the same day each week, at any time of day regardless of meals. The 160-hour half-life provides consistent plasma concentrations throughout the dosing interval.

Combination Dosing (CagriSema): In the CagriSema trials, both cagrilintide and semaglutide are co-titrated: cagrilintide escalates from 0.25 mg to 2.4 mg while semaglutide escalates from 0.25 mg to 2.4 mg, both weekly. The combination is administered as a single injection using a co-formulation device, simplifying the protocol. Use our peptide calculator for reconstitution volume calculations if working with research-grade material.

Duration: Weight management research protocols typically span 52–68 weeks. Weight loss with cagrilintide follows a characteristic pattern: minimal loss in weeks 1–4 (titration period), accelerating loss in weeks 4–26 (maximal efficacy phase), and plateau at weeks 40–52 as a new metabolic set point is approached. Extended trials (>68 weeks) are evaluating weight maintenance durability.

Cagrilintide's safety profile has been characterized across multiple clinical trials involving over 2,000 participants:

Gastrointestinal Effects: Nausea is the most common side effect, affecting 30–45% of participants at the 4.5 mg dose (vs. 6% with placebo). However, nausea is predominantly mild-to-moderate, peaks during dose escalation, and diminishes significantly by week 8–12 of stable dosing. Vomiting occurs in 8–12% and diarrhea in 10–15%. The gradual dose titration protocol was specifically designed to minimize these GI effects. Discontinuation due to GI side effects occurred in approximately 6% of participants at the highest dose.

Injection Site Reactions: Mild injection site reactions (redness, swelling, itching) occurred in 5–8% of participants, generally resolving within 24–48 hours. No injection site infections were reported in pivotal trials.

Cardiovascular Safety: No cardiovascular safety signals have been identified. Heart rate increases of 1–3 bpm were observed (similar to other incretin-based therapies), but no clinically significant arrhythmias or cardiovascular events attributable to cagrilintide were reported. The ongoing REDEFINE cardiovascular outcomes trial will provide definitive cardiovascular safety data.

Pancreatitis Monitoring: As with all incretin and amylin-based therapies, pancreatitis is a monitored event. In cagrilintide trials, the incidence of pancreatitis was not statistically different from placebo (0.1% vs. 0.1%). Lipase and amylase elevations occurred in 7–10% of participants but were not associated with clinical pancreatitis.

Lean Mass Preservation: A concern with rapid weight loss is lean mass loss. In cagrilintide trials, approximately 60–65% of weight lost was fat mass, with 35–40% lean mass — consistent with pharmacological weight loss interventions generally. Resistance exercise and adequate protein intake (≥1.2 g/kg) during treatment may improve the fat-to-lean mass loss ratio. Learn more about body composition optimization in our muscle growth guide.

The combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) represents a paradigm shift in metabolic peptide research — the first clinically validated dual-pathway approach to appetite regulation:

Neuroanatomical Complementarity: GLP-1 receptors are concentrated in the hypothalamic arcuate nucleus and paraventricular nucleus, mediating appetite reduction through melanocortin pathway activation. Amylin receptors are concentrated in the area postrema and nucleus tractus solitarius, mediating satiation through hindbrain circuits. These pathways converge but are not redundant — activating both produces additive or synergistic appetite suppression.

Temporal Complementarity: GLP-1 signaling primarily reduces between-meal hunger (satiety), while amylin signaling primarily reduces within-meal food intake (satiation). The combination addresses both dimensions of appetite — subjects eat less at each meal and experience less hunger between meals. This dual coverage explains why weight loss with CagriSema exceeds the sum of its individual components.

Metabolic Complementarity: Semaglutide improves insulin sensitivity and beta cell function through GLP-1R-mediated pathways. Cagrilintide suppresses glucagon and slows gastric emptying through amylin pathways. Together, they provide more comprehensive metabolic control than either agent alone — particularly relevant for individuals with concurrent obesity and type 2 diabetes.

Research Implications: The success of the cagrilintide-semaglutide combination has catalyzed research into other multi-pathway approaches. Triple combinations targeting amylin + GLP-1 + GIP receptors are in preclinical development. The conceptual framework — that obesity is a multi-pathway disease requiring multi-pathway treatment — represents a fundamental shift in metabolic research thinking. For context on other metabolic peptides, explore our Lipo-C peptide guide.

Cagrilintide research is evolving rapidly, with several developments poised to expand its utility:

Regulatory Timeline: Novo Nordisk has submitted CagriSema for FDA review, with a decision expected in late 2026. If approved, CagriSema would be the first combination amylin-GLP-1 therapy for obesity, establishing a new treatment paradigm. European Medicines Agency submission is expected to follow the FDA decision by approximately 6 months.

Oral Formulations: While current cagrilintide requires injection, oral amylin analog formulations are in early development. The success of oral semaglutide (Rybelsus) has demonstrated that peptide oral bioavailability is achievable with appropriate absorption enhancers. Oral cagrilintide would significantly improve patient convenience and compliance.

Expanded Indications: Beyond obesity, cagrilintide is being investigated for non-alcoholic steatohepatitis (NASH), where its combination of weight reduction and metabolic improvement addresses multiple disease drivers. Additional research is exploring cagrilintide in heart failure with preserved ejection fraction (HFpEF), where obesity-related hemodynamic burden is a key pathological factor.

Personalized Combination Therapy: Research is moving toward personalized peptide combinations based on individual metabolic phenotyping. Subjects with high amylin levels but low GLP-1 sensitivity may benefit more from GLP-1-targeted therapy, while those with amylin deficiency may respond preferentially to cagrilintide. Biomarker-guided treatment selection could optimize outcomes and minimize unnecessary exposure.

The emergence of cagrilintide underscores a broader theme in metabolic peptide research — the most effective interventions often target the endogenous hormonal systems that obesity has disrupted, restoring physiological appetite regulation rather than imposing pharmacological appetite suppression. Browse our research peptide catalog for verified compounds, and visit our about page for quality standards.